Steven Cohen's PYXS Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 37,092 shares of Pyxis Oncology, Inc. (PYXS) worth $111,647, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Steven Cohen has maintained this position in PYXS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 188,136 shares. Largest reduction occurred in Q2 2023, reducing 251,800 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Pyxis Oncology (PYXS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pyxis Oncology (PYXS) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +5,086 | Add 15.89% | 37,092 | $3.01 |
| Q1 2026 | -156,130 | Reduce 82.99% | 32,006 | $1.46 |
| Q4 2025 | +188,136 | New Buy | 188,136 | $1.15 |
| Q2 2023 | -251,800 | Sold Out | 0 | $0.00 |
| Q1 2023 | +251,800 | New Buy | 251,800 | $4.01 |
Steven Cohen's Pyxis Oncology Investment FAQs
Steven Cohen first purchased Pyxis Oncology, Inc. (PYXS) in Q1 2023, acquiring 251,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Pyxis Oncology, Inc. (PYXS) for 5 quarters since Q1 2023.
Steven Cohen's largest addition to Pyxis Oncology, Inc. (PYXS) was in Q1 2023, adding 251,800 shares worth $1.01 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 37,092 shares of Pyxis Oncology, Inc. (PYXS), valued at approximately $111,647.
As of the Q2 2026 filing, Pyxis Oncology, Inc. (PYXS) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Pyxis Oncology, Inc. (PYXS) was 251,800 shares, as reported at the end of Q1 2023.